Titill: | Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits |
Höfundur: |
|
Útgáfa: | 2018-07 |
Tungumál: | Enska |
Umfang: | 1977-1983 |
Háskóli/Stofnun: | Háskóli Íslands University of Iceland |
Svið: | Heilbrigðisvísindasvið (HÍ) School of Health Sciences (UI) |
Deild: | Lyfjafræðideild (HÍ) Faculty of Pharmaceutical Sciences (UI) |
Birtist í: | Drug Design, Development and Therapy;12 |
ISSN: | 1177-8881 |
DOI: | 10.2147/DDDT.S167926 |
Efnisorð: | Pharmacology; Drug Discovery; Pharmaceutical Science; Lyfjafræði; Lyfjaefnafræði; Lyfhrifafræði |
URI: | https://hdl.handle.net/20.500.11815/856 |
Útdráttur:Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia.
Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model.
Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p < 0.01). PP13 elimination half-life was also found to be different between the groups (p < 0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%.
Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated.
|
|
Leyfi:This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
|